BY MARKETWIRE
-
Demant closes KIND acquisition: Expects slightly lower top-line contribution next year – but with good synergies
The procurement of German firm KIND is anticipated to create a boost in profits of USD 311.5 million, compared to the previous assumption of USD 342.7 million.
-
Bavarian Nordic invites shareholders for a December meeting
The injection supplier has actually undergone some turbulent months, as both personal equity funds Permira and Nordic Funding just recently tried to take control of the business.
-
Analyst surprised by Lundbeck’s brief bidding war
Nonetheless, the expert likewise explains that Lundbeck has actually been disciplined in its resources appropriation method.
-
Jyske Bank sees no surprises in Novo’s Medicare discounts
The United States federal government has actually protected a 71% price cut on the retail price of Novo Nordisk’s very popular GLP-1 medications Ozempic and Wegovy for people…
-
Bavarian Nordic invites shareholders for a December meeting
The vaccine manufacturer has gone through some tumultuous months, as the two private equity funds Permira and Nordic Capital recently attempted to take over the company.
-
Novo Nordisk’s new chairman was saved by the fund’s shares
61.3% of investors did not sustain Lars Rebien Sørensen as the brand-new chair of the board.
-
Analysts point to muted effects of new net prices at Medicare
Novo Nordisk’s semaglutide-based medicines Ozempic and Wegovy are amongst the freshly worked out web costs.
-
Analyst impressed by Novo Nordisk’s new amycretin data
Sydbank elderly expert Søren Løntoft Hansen thinks that Tuesday’s stage 2 information might place amycretin highly in connection with existing medications on the marketplace.
-
Analyst on failed Novo study: “Really difficult to demonstrate success”
Before Monday’s arise from Novo Nordisk, Sydbank’s elderly expert Søren Løntoft Hansen had not factored in any kind of worth from the Alzheimer’s research study.
-
Roche obtains promising trial data with breast cancer tablet
In the research study, medication giredestrant has actually aided ladies with a kind of very early bust cancer cells, permitting them to live longer without the illness proceeding.
